九安醫療(002432.SZ):加速推動糖尿病診療照護“O+O”新模式在中國、美國的落地是公司的核心戰略之一
格隆匯6月30日丨有投資者向九安醫療(002432.SZ)提問,“今天一直在重温九安的年報,首先要表揚鄔董祕的寫作能力,可惜只是2022年的經營總結寫的太多了,其實中些東西投資者從年報數據中就抗原自己悟出道理,毋須贅述!到是2023年的經營計劃和未來發展規劃寫的不咋滴!請問:糖尿病0+0今年準備達到推進多少家?(美國+中國);爆款產品中抗原估計仍舊有多少市場(美國訂單和亞馬遜銷售量);其他爆款產品準備提升多少比例;新研發的血壓連續檢測儀和血糖連續”
九安醫療回覆稱,加速推動糖尿病診療照護“O+O”新模式在中國、美國的落地是公司的核心戰略之一,公司集中精力和資源推廣相關業務。為保證信息披露公平性,公司會在定期報吿中披露實際落地城市和醫院數量,敬請關注。糖尿病照護服務是公司的募投項目之一,計劃於2025年完成在全國共開設約600家照護中心的目標,該項目目前正處於加速推廣階段,公司會力爭儘早達成目標。公司會繼續加大在互聯網醫療領域的投入,服務更多的糖尿病患者。產品銷售情況敬請關注公司定期報吿。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.